Poseida Therapeutics executive chairman sells stock for $278,100 By...

Published on 27 Nov 2024 on Investing.com

SAN DIEGO—Mark J. Gergen, the Executive Chairman of Poseida Therapeutics, Inc. (NASDAQ:PSTX),...

Read the rest of the article

Start tracking your investments with Statfolio

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the...

Zacks · via Yahoo Finance 13 Dec 2024

From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pi...

Zacks · via Yahoo Finance 28 Nov 2024

SAN DIEGO—Mark J. Gergen, the Executive Chairman of Poseida Therapeutics, Inc. (NASDAQ:PSTX),...

Investing.com 27 Nov 2024

The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). Whi...

Zacks · via Yahoo Finance 27 Nov 2024

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the...

Zacks · via Yahoo Finance 27 Nov 2024

On Tuesday, Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced an agreement to be acquired by Roc...

Investing.com 26 Nov 2024

Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Hold...

Invezz 26 Nov 2024

On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PS...

Benzinga · via Yahoo Finance 26 Nov 2024

Poseida Therapeutics, Inc. (NASDAQ:PSTX) shareholders will have a reason to smile today, with the...

Simply Wall St. via Yahoo Finance 3 May 2024

Poseida Therapeutics, Inc. (NASDAQ:PSTX) just released its latest full-year results and things ar...

Simply Wall St. via Yahoo Finance 10 Mar 2024